Levalbuterol nebulizer solution: Is it worth five times the cost of Albuterol?

Pharmacotherapy

Volumn 20, Issue 2, 2000, Pages 123-129

  Asmus, Michael J ^a   Hendeles, Leslie ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVALBUTEROL; SALBUTAMOL;

ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHILD; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HEALTH CARE COST; HUMAN; SHORT SURVEY;

EID: 0033958795     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.3.123.34776     Document Type: Short Survey

References (28)

1. Handley DA. R-albuterol. Preclinical and clinical pharmacology of R-albuterol. From molecule 10 man. Clin Rev Allergy Immunol 1996;14:1-2.
2. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1956;12:81-94.
3. Green SA, Nelson HS. Adrenergic agents. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. Allergy: principles and practice, 5th ed. St. Louis: CV Mosby, 1998:571-88.
4. Ahrens RC, Smith GD. Albuterol: an adrenergic agent used in the treatment of asthma pharmacology, pharmacokinetics, and clinical use. Pharmacotherapy 1984;14:105-21.
5. Nelson HS. β-Adrenergic bronchodilators. N Engl J Med 1995;333:499-506.
6. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997;52:458-64.
7. Prior C, Leonard MB, McCullough JR. Effects of the enantiomers of R,S-albuterol on incompletely fused tetanic contractions of slow-and fast-twitch skeletal muscles of the guinea pig. Br J Pharmacol 1998;123:558-64.
8. Zhang XY, Zhu FX, Olszewski MA, Robinson NE. Effects of enantiomers of beta 2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998;274: L32-8.
9. 2 adrenoreceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997;52:849-52.
10. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998;38:1096-106.
11. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea pigs to racemic mixtures and customers of beta 2-selective-sympathomimetics. Pulm Pharmacol 1994;7:367-76.
12. Yamaguchi H, McCullough JR. S-Albuterol exacerbates calcium response to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol 1996;14:47-55.
13. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of deaih and near death from asthma. N Engl J Med 1992;326:501-6.
14. Perrin-Fayolle M. Salbutamol in the treatment of asthma. Lancet 1995;346:1101.
15. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136-41.
16. Schemekel B, Rydberg I, Norlander B, Sjöswärd KN, Ahlner J, Andersson RGG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999;13:1230-5.
17. Perrin-Fayolle M, Blum PS, Morley J, Grosclaude M, Chambe MT. Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996;14:139-47.
18. Cockcroft DW, Swystun VA. Effect of single doses of S-albuterol, R-albuterol, racemic albuterol, and placebo on the airway response to methacholine. Thorax 1997;52:845-8.
19. Cockcroft DW, Davis BE, Swystun VA, Marciniuk DD. Tolerance to the bronchoprotective effect of β2-agonists: comparison of the enantiomers of albuterol with racemic albuterol and placebo. J Allergy Clin Immunol 1999;103: 1049-53.
20. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943-52.
21. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615-21.
22. Sepracor Inc. Xopenex (levalbuterol) package insert. Marlborough, MA; 1999.
23. National Asthma Education and Prevention Program. Expert panel report-2: guidelines for the diagnosis and management of asthma. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, 1997:70.
24. Joad JP, Ahrens RC, Lindgren SD, Weinberger MM. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987;79:78-85.
25. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
26. Newman SP, Clarke SW. Therapeutic aerosols - physical and practical considerations. Thorax 1983;38:881-6.
27. Nelson HS, Spector SL, Whitsett TL, George RB, Dwek JH. The bronchodilator response to inhalation of increasing doses of aerosolized albuterol. J Allergy Clin Immunol 1983;72:371-5.
28. Barnes PJ, Pride NB. Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br J Clin Pharmacol 1983;15:677-82.